Get the Stockscreener App
1.49
1.97%
-0.03
After Hours:
1.56
0.07
+4.70%
20 20 Biolabs Inc stock is traded at $1.49, with a volume of 53,667.
It is down -1.97% in the last 24 hours and down -18.58% over the past month.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
See More
Previous Close:
$1.52
Open:
$1.49
24h Volume:
53,667
Relative Volume:
0.28
Market Cap:
$15.62M
Revenue:
$1.85M
Net Income/Loss:
$-5.26M
P/E Ratio:
-1.5764
EPS:
-0.9452
Net Cash Flow:
-
1W Performance:
-3.86%
1M Performance:
-18.58%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.48
$1.57
1-Week Range:
$1.45
$1.67
52-Week Range:
$1.45
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.49 | 15.93M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
20 20 Biolabs Inc Stock (AIDX) Latest News
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
20/20 Biolabs Inc. (AIDX) Earnings Yield (TTM) - Zacks Investment Research
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Is 20/20 Biolabs (AIDX) stock a strong buy |Bond Issuance - Newser
20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Gross Margin (TTM) - Zacks Investment Research
20/20 BioLabs blood test platform targeting early detection of hard-to-screen Cancers - Proactive financial news
20/20 Biolabs (NASDAQ: AIDX) cuts warrant price, registers 15.16M shares - Stock Titan
Warrant strike cut to $2.25 as 20/20 Biolabs (NASDAQ: AIDX) registers 10.1M shares - Stock Titan
Streeterville warrant repricing at 20/20 Biolabs (NASDAQ: AIDX) drops strike - Stock Titan
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart - MEXC
AIDX (20/20 Biolabs) highlights rising clinical test adoption as core growth driver in latest quarterly earnings.Community Trade Ideas - Newser
How to Value 20/20 Biolabs (AIDX) Stock (Technical Strength) 2026-04-22Community Driven Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX | 20/20 Biolabs, Inc. Common Insider Trading - Quiver Quantitative
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
20/20 Biolabs (NASDAQ: AIDX) resale prospectus: 10.105M shares may be sold - Stock Titan
15.16M shares available for resale as 20/20 Biolabs (NASDAQ: AIDX) direct listing - Stock Titan
[EFFECT] 20/20 Biolabs, Inc. SEC Filing - Stock Titan
AIDX: 20/20 Biolabs Inc.Comparison to Industry - Zacks Investment Research
Dividend History20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform - Sahm
Multi-Cancer Early Detection Test Added to Evexia Diagnostics Platform - Clinical Lab Products
Cancer test reaches 40,000 practitioners through Evexia platform - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The Desert Sun
20/20 Biolabs (AIDX) CFO receives 100,000-share stock option grant - Stock Titan
COO of 20/20 Biolabs (AIDX) granted 150,000 options at $1.88 - Stock Titan
Resale of 10.1M 20/20 Biolabs (Nasdaq: AIDX) shares amid losses - Stock Titan
20/20 Biolabs (NASDAQ: AIDX) 15.16M-share resale registration - Stock Titan
AIDX : 20/20 Biolabs Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance Singapore
20/20 BioLabs (AIDX) Reports 17% Revenue Growth in 2025 and Eyes Significant Expansion in 2026 with AI-Powered Cancer Detection Blood Tests - Minichart
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - The Manila Times
All News for AIDX : 20/20 Biolabs Inc. - Zacks Investment Research
20/20 BioLabs (AIDX) grows 2025 revenue 17% and narrows annual net loss - Stock Titan
20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74)M - TradingView — Track All Markets
20/20 Biolabs (NASDAQ: AIDX) outlines AI blood tests, longevity and growth - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Maryland funds firefighter cancer tests as 20/20 lifts margins - Stock Titan
AIDX | 20/20 Biolabs, Inc. Common Institutional Ownership - Quiver Quantitative
AIDX | 20/20 Biolabs, Inc. Common Stock Data, Price & News - Quiver Quantitative
20/20 Biolabs Unchanged on News - Baystreet.ca
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest - TipRanks
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - The Manila Times
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test - Bitget
20/20 BioLabs licenses kidney disease prediction technology By Investing.com - Investing.com India
20/20 BioLabs Secure U.S. License For Advanced CKD Prediction Technology - RTTNews
20 20 Biolabs Inc Stock (AIDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):